# Pembrolizumab + Capecitabine／Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive

> **NCT04249739** · PHASE2 · UNKNOWN · sponsor: **Samsung Medical Center** · enrollment: 93 (actual)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04249739
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09-29
- **Primary completion:** 2024-02-06
- **Final completion:** 2025-03
- **Target enrollment:** 93 (ACTUAL)
- **Last updated:** 2024-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04249739

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04249739, "Pembrolizumab + Capecitabine／Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT04249739. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*